Advertisement

Control of cisplatin induced emesis — A multidisciplinary intervention strategy

  • Carl Johan Fürst
  • Sussanne Johansson
  • Mats Fredrikson
  • Timo Hursti
  • Gunnar Steineck
  • Curt Peterson
Article
  • 15 Downloads

Abstract

A pharmacological, behavioural and nursing intervention strategy was evaluated for prevention of cisplatin (50 mg m-2) induced emesis in ovarian cancer patients. 46 patients received metoclopramide 2.5 mg kg-1 i.V., b.i.d., dexamethasone 20 mg i.V., lorazepam and biperiden as well as training in relaxation, nutritional advice and continuity in nursing care. Controls (n = 34) received standard treatment (metoclopramide 10-20 mg i.v. or dixyracin 20 mg i.V.). The intensity and duration of nausea and vomiting were significantly lower and measures of quality of life higher for patients on the experimental ward during the three cycles that were studied. No significant changes in emesis were observed between the cycles. There was no correlation between emesis and any of the parameters of quality of life measured. The reliability and validity of nausea ratings are discussed and we suggest that an underreporting of nausea and vomiting might be common.

Key Words

Nausea Vomiting Cisplatin Ovarian cancer Metoclopramide Relaxation Nursing Diet Multidisciplinary 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Coates A, Abraham S, Kaye S, Sowerbutts T: On the receiving end—patient’s perception of the side effects of cancer chemotherapy.Eur J Cancer Clin Oncol 19, 203–208 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    Moynihan C: Testicular cancer. The psychosocial problems of patients and their relatives.6, 477–510 (1987).Google Scholar
  3. 3.
    Loescher L, Clark L, Leigh S: The impact of cancer experience on long-term survivors.Onc Nurs Forum 17, 223–229 (1990).Google Scholar
  4. 4.
    Morrow G: Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behaviourial interventions.Clin Psych Rev 8, 517–556 (1988).CrossRefGoogle Scholar
  5. 5.
    Hursti T, Fredrikson M, Johansson S, Fürst C: Extinction of conditioned nausea after chemotherapy is associated with personality differences. Submitted for publication (1991).Google Scholar
  6. 6.
    Kris M, Gralla R, Clarke R: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone.Cancer 60, 2816–3822 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    Carey P, Burish T: Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion.Psych Bull 104 (3), 307–325 (1988).CrossRefGoogle Scholar
  8. 8.
    Burish T, Carey M, Krozely M, Greco F: Conditioned side effects induced by cancer chemotherapy: Prevention through behaviourial treatment.J Consult Clin Psychol 55, 42–48 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    Mattess R D, Arnold C, Boraas M: Learned food aversions among cancer chemotherapy patients.Cancer 60, 2576–2580 (1987).CrossRefGoogle Scholar
  10. 10.
    Jacobsen P B, Andrykowski M A, Redd W H,et al.: Non-pharmacological factors in the development of posttreatment nausea with adjuvant chemotherapy for breastcancer.Cancer 61, 379–385 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    Martin M, Diaz-Rubio E, Casado A, Dominguez S: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.EJC 28 (2/3), 430–433 (1992).CrossRefGoogle Scholar
  12. 12.
    Cubeddou L X, Hoffman I S, Fuenmayor N T, Finn A L: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.NEJM 322 (12), 810–316 (1990).Google Scholar
  13. 13.
    Marty M, Pouillart P, Scholl S,et al.: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.NEJM 322 (12), 816–821 (1990).PubMedGoogle Scholar
  14. 14.
    Khojasteh A, Sartiano G, Tapazoglou R,et al.: Ondansetron for the prevention of emesis induced by high-dose cisplatin.Cancer 66, 1101–1105 (1990).PubMedCrossRefGoogle Scholar
  15. 15.
    Johansson S, Steineck G, Hursti T, Fredrikson M, Fürst C J, Peterson C: Ondansetron: a pilot study of chemotherapyinduced acute and delayed emesis and a comparison with historical controls. Acta Oncol (in press) (1991).Google Scholar

Copyright information

© Humana Press Inc. 1992

Authors and Affiliations

  • Carl Johan Fürst
    • 1
  • Sussanne Johansson
    • 1
  • Mats Fredrikson
    • 3
  • Timo Hursti
    • 3
  • Gunnar Steineck
    • 1
  • Curt Peterson
    • 2
  1. 1.Dept. of General OncologyRadiumhemmet, Karolinska HospitalStockholmSweden
  2. 2.Dept. of Clinical PharmacologyKarolinska Institute and HospitalStockholmSweden
  3. 3.Dept. of Medical PsychologyKarolinska Institute and HospitalStockholmSweden

Personalised recommendations